• Zum Hauptinhalt springen
  • Zum Footer springen

PSY-PGx

  • About
    • Mission
    • Management & Structure
  • Consortium
  • Research
    • Work Packages
    • Careers
    • Publications
    • Clinical Study
  • Patients
    • Local Websites
    • Clinical Study
  • Media
    • Patient Experiences with Pharmacogenetics
    • Press Releases
    • Patient Inclusion
    • X (formerly Twitter)
  • Internal
  • Events
  • Meet the Team
  • News
  1. PSY-PGx
  2. Research
  3. Work Packages
  4. WP2: Ethical, Legal & Societal Issues (ELSI)

WP2: Ethical, Legal & Societal Issues (ELSI)

Lead

Universitatea Babeş-Bolyai

Department of Psychology

Dr. Ramona Moldovan

Ludwig-Maximilians-Universität München

Institute of Psychiatric Phenomics and Genomics

Dr. Urs Heilbronner

Participants/Support

  • Global Alliance of Mental Illness Advocacy Networks
  • 
World Psychiatric Association

  • Parnassia Groep BV

Goals

  • Define the project security policy and assess the implications and impact on different factors (ethical, psychosocial and economic) that will determine the future adoption of the PSY- PGx approach.
  • Provide reliable information to stakeholders within different healthcare systems across Europe and beyond.

PSY-PGx

A New Intervention for Implementation of Pharmacogenetics in Psychiatry
PSY-PGx Coordinator

Roos van Westrhenen

Psychiatrist & Clinical Pharmacologist (MD, PhD) Parnassia Psychiatric Institute/St. John’s National Academy of Health Sciences, Bangalore, India/King’s College London

Overschiestraat 57
1062 HN Amsterdam, The Netherlands
p qguéicbpziuiuöcјæ-uä

Sitemap

About
Consortium Members
Research
Patients
News
Internal


Funding

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 945151.

Twitter
Editor login
Imprint | Data-Safety